UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2024
Commission File No. 001-39621
OPTHEA LIMITED
(Translation of registrant’s name into English)
Level 4
650 Chapel Street
South Yarra, Victoria, 3141
Australia
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
Exhibit |
|
Description |
99.1 |
|
Press Release: Opthea to Participate in the Leerink Partners Global Biopharma Conference |
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
OPTHEA LIMITED |
|
|
(Registrant) |
|
|
|
|
|
By: |
/s/ Frederic Guerard |
|
Name: |
Frederic Guerard |
|
Title: |
Chief Executive Officer |
Date: 03/06/2024
Exhibit 99.1
ASX, Nasdaq and Media Release
06 March 2024
Opthea to Participate in the Leerink Partners Global Biopharma Conference
Melbourne, Australia, 06 March 2024, and Princeton, New Jersey, 05 March 2024 – Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
About Opthea
Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe,NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.
Authorized for release to ASX by Fred Guerard, CEO
Investor Enquiries |
Join our email database to receive program updates: |
PJ Kelleher LifeSci Advisors Email: pkelleher@lifesciadvisors.com
Media
Silvana Guerci-Lena NorthStream Global Partners silvana@nsgpllc.com |
Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com
|